Odyssey Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	0.1	2.98	4.47	1.04	-
Revenue Growth	-97.79%	-33.45%	331.24%	-	-
Gross Profit	0.1	2.98	4.47	1.04	-
Selling, General & Admin	34.21	37.52	27.12	22.2	21.02
Research & Development	126.16	126.62	112.58	112.28	101.76
Other Operating Expenses	11.01	-4.05	1.8	0.3	5.13
Total Operating Expenses	171.38	160.09	141.49	134.77	127.9
Operating Income	-171.28	-157.11	-137.02	-133.74	-127.9
Interest Income	8.86	6.35	8.49	8.79	3.92
Interest Expense	-0.04	-0.02	-0.02	-0.34	-0.29
Other Non-Operating Income (Expense)	1.28	1.2	-0.3	-0.21	-0.05
Total Non-Operating Income (Expense)	10.09	7.54	8.17	8.25	3.59
Pretax Income	-161.07	-149.57	-128.85	-125.49	-124.32
Provision for Income Taxes	-1.04	-0.93	0.47	0.45	0.35
Net Income	-160.03	-148.65	-129.32	-125.94	-124.67
Net Income to Common	-160.03	-148.65	-130.4	-130.92	-124.67
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	11	3	1	1	0
Shares Outstanding (Diluted)	11	3	1	1	0
Shares Change	1198.85%	245.30%	35.78%	44.71%	-
EPS (Basic)	9.67	-48.93	-148.21	-202.02	-278.39
EPS (Diluted)	9.67	-48.93	-148.21	-202.02	-278.39
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Free Cash Flow	-132.74	-130.7	-118.24	-117.78	-112.87
Free Cash Flow Growth	-	-	-	-	-
Free Cash Flow Per Share	-11.62	-43.02	-134.38	-181.76	-252.05
Gross Margin	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-173008.00%	-5279.20%	-3063.98%	-12896.40%	-
Profit Margin	-161643.00%	-4994.86%	-2891.79%	-12144.50%	-
FCF Margin	-134080.00%	-4391.80%	-2643.90%	-11358.10%	-
EBITDA	-166.72	-152.2	-131.83	-128.83	-125.14
EBITDA Margin	-168403.00%	-5114.18%	-2947.85%	-12423.10%	-
EBIT	-171.28	-157.11	-137.02	-133.74	-127.9
EBIT Margin	-173008.00%	-5279.20%	-3063.98%	-12896.40%	-
Effective Tax Rate	0.65%	0.62%	-0.36%	-0.36%	-0.28%

SEC Filings: 10-K · 10-Q